REHOVOT, Israel & PHILADELPHIA & MELBOURNE, Australia--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG) (NASDAQ:GENE) (ASX:GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests. Under the terms of the agreement, GTG will market Rosetta Genomics’ miRview™ tests in Australia, New Zealand and Singapore. Further financial terms were not disclosed.
